These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33085848)

  • 21. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.
    Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
    J Clin Oncol; 1999 Jul; 17(7):1974-82. PubMed ID: 10561247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
    Kokate P; Sawaimoon S; Bhatia S; Mandava S
    Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
    Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
    Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
    Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
    J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.
    Gancberg D; Di Leo A; Cardoso F; Rouas G; Pedrocchi M; Paesmans M; Verhest A; Bernard-Marty C; Piccart MJ; Larsimont D
    Ann Oncol; 2002 Jul; 13(7):1036-43. PubMed ID: 12176781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D; Di Leo A; Rouas G; Paesmans M; Ferreira-Filho F; Bernard C; Cardoso F; Verhest A; Piccart MJ; Gancberg D
    Anticancer Res; 2002; 22(4):2485-90. PubMed ID: 12174949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study.
    Yazaki S; Hashimoto J; Ogita S; Nakano E; Suzuki K; Yamauchi T
    Anticancer Drugs; 2020 Oct; 31(9):973-978. PubMed ID: 32868644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profile of HER2 +ve Gastric Cancers in Brunei Darussalam.
    Chong VH; Telisinghe PU; Tan J; Abdullah MS; Chong CF
    Asian Pac J Cancer Prev; 2016; 17(5):2555-8. PubMed ID: 27268629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India.
    Panjwani P; Epari S; Karpate A; Shirsat H; Rajsekharan P; Basak R; Shet T; Chinoy R; Chacko R; Gursale S; Baraskar N; Gupta S; Hawaldar R; Desai S
    Indian J Med Res; 2010 Sep; 132():287-94. PubMed ID: 20847375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
    Dowsett M; Bartlett J; Ellis IO; Salter J; Hills M; Mallon E; Watters AD; Cooke T; Paish C; Wencyk PM; Pinder SE
    J Pathol; 2003 Apr; 199(4):418-23. PubMed ID: 12635131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.
    Olsen DA; Østergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Brandslund I
    Clin Chem Lab Med; 2007; 45(2):177-82. PubMed ID: 17311504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.